In an orthotopic model of 4T1.2 BCs, it was seen that PAPP-A resistant IGFBP-4 retained their tumor suppressive role of sequestering IGFs even in the presence of PAPP-A, representing a novel avenue of IGF-blocking strategies for BC therapeutics [99]. This evidence concerns the gene IGFBP4 and breast cancer.